论文部分内容阅读
采用放免法动态观察了２５只实验性犬ＳＡＨ后ＣＶＳ动物模型的血浆、ＣＳＦ中ＥＴ及ＣＧＲＰ含量变化及巴曲酶的保护作用。结果：单纯注血组及巴曲酶治疗组的血浆、ＣＳＦ中ＥＴ含量较对照组明显增高（Ｐ＜０．０１），ＣＧＲＰ含量明显降低（Ｐ＜０．０１）。单纯注血组在注血后３０ｍｉｎ血浆、ＣＳＦ中ＥＴ含量开始升高，ＣＧＲＰ含量开始下降，至第７ｄＥＴ达最高值，ＣＧＲＰ达最低值。经蛛网膜下腔及静脉注入巴曲酶０．４ＢＵ／ｋｇ／ｄ组，血浆及ＣＳＦ中ＥＴ含量均较同期单纯注血组明显降低（Ｐ＜０．０１），而ＣＧＲＰ则明显升高（Ｐ＜０．０１）。提示血浆、ＣＳＦ中ＥＴ、ＣＧＲＰ失衡是ＳＡＨ后ＣＶＳ的原因之一。巴曲酶可防止ＥＴ升高和ＣＧＲＰ降低。
The changes of ET and CGRP in plasma and CSF, and the protective effect of batroxobin in CVS animal model of 25 experimental dogs after SAH were observed dynamically by radioimmunoassay. Results: Compared with the control group, the content of ET in the plasma and CSF of the simple injection group and the batroxobin group were significantly increased (P <0.01) and the content of CGRP was significantly decreased (P <0.01). In the simple injection group, the content of ET in plasma and CSF began to increase 30min after the injection of blood, the content of CGRP began to decrease, reaching the highest value on the 7th day and the lowest value of CGRP. The levels of plasma ET and ET in plasma and CSF were significantly decreased (P <0.01) and CGRP (P <0.01) in the subarachnoid and intravenous injection of 0.4BU / kg / d batroxobin P <0.01). It is suggested that imbalance of ET and CGRP in plasma and CSF is one of the causes of CVS after SAH. Batroxobin prevents ET elevation and CGRP reduction.